Bruker Corporation Appoints Anthony Mattacchione as Chief Financial Officer
22 February 2016 - 11:01PM
Business Wire
Bruker Corporation (NASDAQ:BRKR) today announced the appointment
of Anthony (‘Tony’) Mattacchione as Chief Financial Officer,
effective immediately. Mr. Mattacchione has served as the Company’s
Interim Chief Financial Officer since June 2015, and he previously
served as Bruker’s Senior Vice President of Finance &
Accounting.
This Smart News Release features multimedia.
View the full release here:
http://www.businesswire.com/news/home/20160222005518/en/
Anthony Mattacchione named CFO of Bruker
Corporation (Photo: Business Wire)
Frank Laukien, Bruker’s President and CEO, stated: “On behalf of
Bruker’s Board and executive management team, I am very pleased to
congratulate Tony on his appointment. Tony has the strategic and
leadership skills, as well as the operational experience and focus,
to assist Bruker in driving continuous improvements in operational
excellence and financial performance. I am convinced that Tony will
be an excellent Chief Financial Officer for Bruker.”
“Tony has been a key leader of the Bruker finance team since he
joined the Company,” added John Ornell, a Bruker director and
member of the Board’s Audit Committee. “Tony has performed
flawlessly in his role as interim CFO, and he has been a very
strong contributor to Bruker in many aspects. I now look forward to
working with Tony as Bruker’s CFO, and to mentoring Tony using my
13 years of experience as a public-company CFO.”
Mr. Mattacchione brings more than thirty years of financial,
accounting, operational and management experience to Bruker’s CFO
position. Prior to becoming Bruker’s Interim CFO in 2015, he had
responsibility for Bruker’s global finance and accounting
functions, including financial planning & analysis, corporate
accounting, public company reporting, treasury, tax, shared
financial services, internal controls and audit, and global ERP
business processes. Mr. Mattacchione has been, and will continue to
be, a key leader in upgrading Bruker’s financial and ERP systems,
and in implementing advanced management processes at Bruker.
Prior to joining Bruker, Mr. Mattacchione served as Chief
Financial Officer of EMD Millipore Corporation, a subsidiary of
Merck KGaA, from 2010 to 2013. Previously, he was Vice President,
Controller and Chief Accounting Officer of Millipore Corporation
between 2006 and 2010. He also held various financial leadership
roles during a 16-year career at Gerber Scientific. Mr.
Mattacchione is a certified public accountant, and holds an MBA
from the University of Connecticut.
Tony Mattacchione commented: “I am delighted and honored to have
been appointed as Bruker’s CFO. It will be a pleasure to work with
our Board, CEO and executive management team to drive Bruker’s next
phase of Operational Excellence, and to lead our financial strategy
of profitable revenue growth, steady margin expansion, further
working capital improvements, high RoIC, and disciplined capital
deployment. I believe Bruker is well on its way to becoming an even
better company - for our customers, our employees and our
shareholders.”
About Bruker Corporation
For more than 50 years, Bruker has enabled scientists to make
breakthrough discoveries and develop new applications that improve
the quality of human life. Bruker’s high-performance scientific
research instruments and high-value analytical solutions enable
scientists to explore life and materials at molecular, cellular and
microscopic levels.
In close cooperation with our customers, Bruker is enabling
innovation, productivity and customer success in life science
molecular research, in applied and pharma applications, and in
microscopy, nano-analysis and industrial applications, as well as
in cell biology, preclinical imaging, clinical research,
microbiology and molecular diagnostics. For more information,
please visit: http://www.bruker.com.
Forward Looking Statements
Any statements contained in this press release that do not
describe historical facts may constitute forward-looking statements
as that term is defined in the Private Securities Litigation Reform
Act of 1995. Any forward-looking statements contained herein are
based on current expectations, but are subject to risks and
uncertainties that could cause actual results to differ materially
from those projected, including, but not limited to, risks and
uncertainties relating to adverse changes in conditions in the
global economy and volatility in the capital markets, the
integration of businesses we have acquired or may acquire in the
future, our ability to successfully implement our restructuring
initiatives, changing technologies, product development and market
acceptance of our products, the cost and pricing of our products,
manufacturing, competition, dependence on collaborative partners
and key suppliers, capital spending and government funding
policies, changes in governmental regulations, realization of
anticipated benefits from economic stimulus programs, intellectual
property rights, litigation, exposure to foreign currency
fluctuations and other risk factors discussed from time to time in
our filings with the Securities and Exchange Commission. These and
other factors are identified and described in more detail in our
filings with the SEC, including, without limitation, our annual
report on Form 10-K for the year ended December 31, 2014 and
subsequently filed Quarterly Reports on Form 10-Q. We expressly
disclaim any intent or obligation to update these forward-looking
statements other than as required by law.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160222005518/en/
Bruker CorporationJoshua Young, +1-978-667–9580, ext.
1479Vice President, Investor Relations & Corporate
Developmentjoshua.young@Bruker.com
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Jul 2023 to Jul 2024